Evotec (EVO) said Monday it has nominated the first small molecule preclinical development candidate from its multi-target drug discovery collaboration in medical dermatology with Almirall.
The partnership intends to create novel treatments for immune-mediated inflammatory skin diseases.
The company said it will continue to support the program toward investigational new drug submission.
Evotec shares were up 2.9% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments